Shopping Cart
Remove All
Your shopping cart is currently empty
PI3Kα-IN-4 is a potent, selective, and orally active PI3Kα inhibitor with an IC50 of 1.8 nM, demonstrating antitumor activity [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,400 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $1,820 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $2,500 | 6-8 weeks | 6-8 weeks |
| Description | PI3Kα-IN-4 is a potent, selective, and orally active PI3Kα inhibitor with an IC50 of 1.8 nM, demonstrating antitumor activity [1]. |
| Targets&IC50 | PI3Kα:1.8 nM (IC50) |
| In vitro | PI3Kα-IN-4 (compound 10) inhibits PI3Kα, β, δ, and γ in kinase assays with IC50s of 1.8, 271.0, 13.9, and 13.8 nM, respectively, and in cell-based assays with IC50s of 12.1, 1393, 183, and >10000 nM, respectively [1]. |
| In vivo | PI3Kα-IN-4 (compound 10) (30 mg/kg; p.o. once daily for 21 days) achieves 73.0% tumor growth inhibition in mice. It dose-dependently suppresses tumor growth by 62.5% (15 mg/kg), 86.0% (30 mg/kg), and 90.7% (40 mg/kg) when administered orally once daily for 30 days. Time- and dose-dependent inhibition of Akt phosphorylation is observed in vivo (15-40 mg/kg; p.o. once daily; 1-4 h). The compound shows high Cmax (mouse 22167, rat 2327 nM) and good bioavailability (mouse 59.4%, rat 46.9%) after oral administration (mouse 10, rat 3 mg/kg). Following intravenous injection (mouse 1, rat 1 mg/kg), it has a t1/2 of 0.99 hours in mice and 1.22 hours in rats, with low plasma clearance (mouse 4.16, rat 5.28 mL/min/kg). |
| Synonyms | PI3Kα-IN-4 |
| Molecular Weight | 560 |
| Formula | C25H23ClFN5O5S |
| Cas No. | 2322293-83-2 |
| Smiles | CNC(=O)[C@H](C)Cn1cnc2ccc(cc2c1=O)-c1cnc(OC)c(NS(=O)(=O)c2ccc(F)cc2Cl)c1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (178.57 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (5.89 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.